

FIND THE UNSEEN 13%

KRAS mutations in non-small cell lung cancers are prognostic of poor survival.²
KRAS G12C is the most common, positive in an estimated 13% of patients with NSCLC.¹

KRAS TESTING IS RECOMMENDED IN ADVANCED NSCLC PATIENTS.² – NCCN

KRAS: Kirsten rat sarcoma; NCCN: National Comprehensive Cancer Network

References: 1. Biernacka A et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. *Cancer Genet.* 2016;209(5):195-198. 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer. Version 8.2020 – September 15, 2020. NCCN.org.

© 2020 Amgen Inc. All rights reserved.

AMGEN[®]
Oncology